THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS
The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atheroscleros...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-07-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1699 |
| _version_ | 1826949680362160128 |
|---|---|
| author | O. D. Ostroumova A. I. Kochetkov N. Yu. Voevodina S. S. Sharonova |
| author_facet | O. D. Ostroumova A. I. Kochetkov N. Yu. Voevodina S. S. Sharonova |
| author_sort | O. D. Ostroumova |
| collection | DOAJ |
| description | The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic stroke, ischemic heart disease and lower-extremity arterial disease are given. The current principles of drug therapy are considered from the point of view of improving the prognosis and eliminating ischemia. The basic positions of International and Russian clinical recommendations on the management of patients with the presence of certain clinical manifestations of atherosclerosis are discussed. Detailed administration schemes and the preferred doses of statins and antiplatelet agents depending on the localization of atherosclerotic lesion and the severity of stenosis are described. The target blood lipids levels in the treatment with statins are given. The advantages of statins as drugs that reduce the risk of cardiovascular complications are presented. Current data on the pattern of antiplatelet use, including acetylsalicylic acid, in individuals with clinical manifestations of atherosclerosis are given. The principal tactic of dual antiplatelet therapy and schemes of its use in patients undergoing percutaneous coronary intervention, coronary artery bypass surgery and in individuals with a history of acute coronary disorders are considered. |
| first_indexed | 2024-03-08T14:02:37Z |
| format | Article |
| id | doaj.art-f2f36845d3144b2dba2cff339ff43d4d |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:18:26Z |
| publishDate | 2018-07-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-f2f36845d3144b2dba2cff339ff43d4d2024-12-04T11:48:15ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532018-07-0114342543310.20996/1819-6446-2018-14-3-425-4331491THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTSO. D. Ostroumova0A. I. Kochetkov1N. Yu. Voevodina2S. S. Sharonova3A.I. Evdokimov Moscow State University of Medicine and Dentistry; I.M. Sechenov First Moscow State Medical University (Sechenov University)A.I. Evdokimov Moscow State University of Medicine and DentistryE.O. Mukhin Municipal Clinical HospitalI.M. Sechenov First Moscow State Medical University (Sechenov University)The review focuses on the impairment of the carotid, coronary arteries and lower-extremity arterial disease. Systemic involvement of various vascular beds in atherogenesis is emphasized. Epidemiological characteristics of morbidity and mortality from the main clinical manifestations of atherosclerosis - ischemic stroke, ischemic heart disease and lower-extremity arterial disease are given. The current principles of drug therapy are considered from the point of view of improving the prognosis and eliminating ischemia. The basic positions of International and Russian clinical recommendations on the management of patients with the presence of certain clinical manifestations of atherosclerosis are discussed. Detailed administration schemes and the preferred doses of statins and antiplatelet agents depending on the localization of atherosclerotic lesion and the severity of stenosis are described. The target blood lipids levels in the treatment with statins are given. The advantages of statins as drugs that reduce the risk of cardiovascular complications are presented. Current data on the pattern of antiplatelet use, including acetylsalicylic acid, in individuals with clinical manifestations of atherosclerosis are given. The principal tactic of dual antiplatelet therapy and schemes of its use in patients undergoing percutaneous coronary intervention, coronary artery bypass surgery and in individuals with a history of acute coronary disorders are considered.https://www.rpcardio.online/jour/article/view/1699atherosclerosisischemic strokeischemic heart diseaselower-extremity arterial diseaserosuvastatinacetylsalicylic acidfixed-dose combinationclinical recommendations |
| spellingShingle | O. D. Ostroumova A. I. Kochetkov N. Yu. Voevodina S. S. Sharonova THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS Рациональная фармакотерапия в кардиологии atherosclerosis ischemic stroke ischemic heart disease lower-extremity arterial disease rosuvastatin acetylsalicylic acid fixed-dose combination clinical recommendations |
| title | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS |
| title_full | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS |
| title_fullStr | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS |
| title_full_unstemmed | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS |
| title_short | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS |
| title_sort | possibilities of using a new fixed dose combination of rosuvastatin and acetylsalicylic acid focus groups of patients |
| topic | atherosclerosis ischemic stroke ischemic heart disease lower-extremity arterial disease rosuvastatin acetylsalicylic acid fixed-dose combination clinical recommendations |
| url | https://www.rpcardio.online/jour/article/view/1699 |
| work_keys_str_mv | AT odostroumova thepossibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT aikochetkov thepossibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT nyuvoevodina thepossibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT sssharonova thepossibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT odostroumova possibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT aikochetkov possibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT nyuvoevodina possibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients AT sssharonova possibilitiesofusinganewfixeddosecombinationofrosuvastatinandacetylsalicylicacidfocusgroupsofpatients |